Genotype-guided dosing study of FOLFIRI plus bevacizumab in metastatic colorectal cancer patients

PURPOSE: UGT1A1*28 confers a higher risk of toxicity in patients treated with irinotecan. Patients with *1/*1 and *1/*28 genotypes might tolerate higher than standard doses of irinotecan. We aimed to identify the maximum tolerated dose (MTD) of irinotecan in mCRC patients with *1/*1 and *1/*28 genot...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Toffoli, Giuseppe, Sharma, Manish R., Marangon, Elena, Posocco, Bianca, Gray, Elizabeth, Mai, Quan, Buonadonna, Angela, Polite, Blase N., Miolo, Gianmaria, Tabaro, Gianna, Innocenti, Federico
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6777349/
https://ncbi.nlm.nih.gov/pubmed/27507617
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1012
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars